{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:00:12Z","timestamp":1787742012250,"version":"build-2784847793"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ijantimicag.2023.106844","type":"journal-article","created":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T09:47:56Z","timestamp":1683452876000},"page":"106844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparing novel antibiotics and carbapenems for complicated intra-abdominal infections: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0879-2116","authenticated-orcid":false,"given":"Tim Yi-Ting","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5702-7747","authenticated-orcid":false,"given":"Chi-Kuei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8121-6430","authenticated-orcid":false,"given":"Shun-Chuan","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Song","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Jen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106844_bib0001","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00134-019-05819-3","article-title":"Epidemiology of intra-abdominal infection and sepsis in critically ill patients: \u2018Abses\u2019, a multinational observational cohort study and esicm trials group project","volume":"45","author":"Blot","year":"2019","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0002","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0003","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0004","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13017-021-00387-8","article-title":"WSES\/GAIS\/SIS-E\/WSIS\/AAST global clinical pathways for patients with intra-abdominal infections","volume":"16","author":"Sartelli","year":"2021","journal-title":"World J Emerg Surg"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2023.106844_bib0005","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1093\/infdis\/jiz574","article-title":"Risk factors and molecular epidemiology of complicated intra-abdominal infections with carbapenem-resistant Enterobacteriaceae: a multicenter study in China","volume":"221","author":"Liu","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106354","article-title":"Klebsiella pneumoniae harboring carbapenemase genes in Taiwan: its evolution over 20 years, 1998\u20132019","volume":"58","author":"Lai","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0007","first-page":"1221","article-title":"Extended-spectrum beta-lactamase and carbapenem-resistant Gram-negative pathogens in Makkah, Saudi Arabia","volume":"32","author":"Kabrah","year":"2022","journal-title":"Ethiop J Health Sci"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0008","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3389\/fmicb.2019.01941","article-title":"Understanding the epidemiology of multi-drug resistant Gram-negative bacilli in the Middle East using a One Health approach","volume":"10","author":"Dandachi","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0009","first-page":"1364","article-title":"Epidemiology and susceptibility of pathogens from SMART 2011\u201312 Turkey: evaluation of hospital-acquired versus community-acquired urinary tract infections and ICU- versus non-ICU-associated intra-abdominal infections","volume":"72","author":"Koksal","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijid.2015.04.011","article-title":"Susceptibility trends and molecular characterization of Gram-negative bacilli associated with urinary tract and intra-abdominal infections in Jordan and Lebanon: SMART 2011\u20132013","volume":"35","author":"Hayajneh","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0011","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12879-019-3829-2","article-title":"The 2018 Lebanese Society of Infectious Diseases and Clinical Microbiology guidelines for the use of antimicrobial therapy in complicated intra-abdominal infections in the era of antimicrobial resistance","volume":"19","author":"Haddad","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0012","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/sur.2009.9930","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America","volume":"11","author":"Solomkin","year":"2010","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105970","article-title":"Opportunities for antimicrobial stewardship among carbapenem-treated patients in 18 North American hospitals","volume":"55","author":"Wagner","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0014","doi-asserted-by":"crossref","first-page":"ofaa591","DOI":"10.1093\/ofid\/ofaa591","article-title":"Novel beta-lactam\/beta-lactamase plus metronidazole vs carbapenem for complicated intra-abdominal infections: a meta-analysis of randomized controlled trials","volume":"8","author":"Che","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0015","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3390\/jcm8060866","article-title":"The efficacy and safety of eravacycline in the treatment of complicated intra-abdominal infections: a systemic review and meta-analysis of randomized controlled trials","volume":"8","author":"Lan","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0016","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/antibiotics10010079","article-title":"Ceftolozane-tazobactam combination therapy compared to ceftolozane-tazobactam monotherapy for the treatment of severe infections: a systematic review and meta-analysis","volume":"10","author":"Fiore","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0017","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijantimicag.2019.07.003","article-title":"Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: a systematic review, meta-analysis, and cost-effectiveness analysis","volume":"54","author":"Nguyen","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0018","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/14787210.2018.1429912","article-title":"Novel \u03b2-lactam\/\u03b2-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: a meta-analysis of randomized controlled trials","volume":"16","author":"Chen","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0019","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijid.2022.08.003","article-title":"A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane\/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections","volume":"123","author":"Sun","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0020","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0021","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0022","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/INF.0000000000002392","article-title":"Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children \u22653 months to <18 years with complicated intra-abdominal infection: results from a phase 2, randomized, controlled trial","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0023","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0024","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0025","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0026","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0027","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0028","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.01614-13","article-title":"Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections","volume":"58","author":"Solomkin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0029","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0030","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0031","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"Ignite4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0032","doi-asserted-by":"crossref","first-page":"e02584","DOI":"10.1128\/AAC.02584-17","article-title":"In vitro activity of ceftazidime-avibactam against isolates from patients in a phase 3 clinical trial for treatment of complicated intra-abdominal infections","volume":"62","author":"Stone","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0033","first-page":"e01715","article-title":"In vitro activity of eravacycline against Gram-positive bacteria isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0034","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01854-22","article-title":"In vitro activity of new \u03b2-lactam-\u03b2-lactamase inhibitor combinations and comparators against clinical isolates of Gram-negative bacilli: results from the China Antimicrobial Surveillance Network (CHINET) in 2019","volume":"10","author":"Guo","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.114925","article-title":"In vitro activity of ceftolozane\/tazobactam against phenotypically defined extended-spectrum \u03b2-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016)","volume":"96","author":"Karlowsky","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0036","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2147\/IDR.S175679","article-title":"In vitro activity of ceftazidime-avibactam, ceftolozane-tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)","volume":"11","author":"Jean","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0037","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00189-22","article-title":"In vitro activity of ceftolozane-tazobactam, imipenem-relebactam, ceftazidime-avibactam, and comparators against Pseudomonas aeruginosa isolates collected in United States hospitals according to results from the SMART surveillance program, 2018 to 2020","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0038","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40264-020-00934-3","article-title":"Safety profile of ceftazidime-avibactam: pooled data from the adult phase II and phase III clinical trial programme","volume":"43","author":"Cheng","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0039","doi-asserted-by":"crossref","DOI":"10.1177\/20420986211027096","article-title":"The safety of ceftolozane-tazobactam for the treatment of acute bacterial infections: a systemic review and meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0040","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jgar.2021.02.009","article-title":"Efficacy and safety of eravacycline: a meta-analysis","volume":"24","author":"Eljaaly","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0041","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3390\/antibiotics11121773","article-title":"Over-prescription and overuse of antimicrobials in the Eastern Mediterranean Region: the urgent need for antimicrobial stewardship programs with access, watch, and reserve adoption","volume":"11","author":"Talaat","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0042","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.46.2001537","article-title":"Swiss Centre for Antibiotic Resistance (ANRESIS). Antimicrobial resistance and antibiotic consumption in intensive care units, Switzerland, 2009 to 2018","volume":"26","author":"Barnsteiner","year":"2021","journal-title":"Euro Surveill"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0043","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/jcpt.12791","article-title":"Correlation between antimicrobial consumption and the prevalence of carbapenem-resistant Escherichia coli and carbapenem-resistant Klebsiella pneumoniae at a university hospital in Thailand","volume":"44","author":"Prakobsrikul","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ijantimicag.2023.106844_bib0044","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-0711-13-7","article-title":"Effects of carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients","volume":"13","author":"Ogutlu","year":"2014","journal-title":"Ann Clin Microbiol Antimicrob"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:45:16Z","timestamp":1760377516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923001231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0924857923001231"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106844","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing novel antibiotics and carbapenems for complicated intra-abdominal infections: a systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106844","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106844"}}